Portal de investigación
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Wong, Sandy W.
- Bar, Noffar
- Paris, Laura
- Hofmeister, Craig C.
- Hansson, Markus
- Santoro, Armando
- Mateos, Maria-Victoria
- Rodriguez-Otero, Paula
- Lund, Johan
- Encinas, Cristina
- Yee, Andrew J.
- Oriol, Albert
- Cerchione, Claudio
- Ferstl, Barbara
- Carlson, Kristina
- Ribas, Paz
- Bermudez, Arancha
- Boss, Isaac W.
- Gaudy, Allison
- Li, Shaoyi
- Hsu, Kevin
- Godwin, Colin D.
- Burgess, Michael R.
- San-Miguel, Jesus
- Costa, Luciano J.
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Blood AMER SOC HEMATOLOGY
Citas Recibidas en Web of Science: 11
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Wong,SW,Bar,N,Paris,L,Hofmeister,CC,Hansson,M,Santoro,A,Mateos,M et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study. 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). 2022. New Orleans-LA. 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA:AMER SOC HEMATOLOGY. 2022.